TET2 and T-cell non-Hodgkin lymphoma: Surveying the genomic landscape of reported CAR+ T-cell lymphomas, TET2 LOF aberrations emerge as a recurrent feature, detected in four of seven examined cases involving a commercial CAR-T product [8, 10, 12, 13].